BIOLINK - TO INVESTIGATE AND DETERMINE IF TREATMENT WITH RAMATROBAN, ADMINISTERED FOR 28 DAYS TO HOSPITALIZED, NON-ICU PATIENTS WITH COVID-19 PNEUMONIA, REDUCES THE RISK OF SUBSEQUENT DEVELOPMENT OF PASC OVER THE ENSUING 11 MONTHS. PROVIDED DATA
- Funded by Biomedical Advanced Research and Development Authority (BARDA)
- Total publications:0 publications
Grant number: 75A50122C00068
Grant search
Key facts
Disease
COVID-19Start & end year
20222025Known Financial Commitments (USD)
$450,000Funder
Biomedical Advanced Research and Development Authority (BARDA)Research Location
United States of AmericaLead Research Institution
BIOLINK LIFE SCIENCES, INC.Research Priority Alignment
N/A
Research Category
Clinical characterisation and managementResearch Subcategory
Post acute and long term health consequencesSpecial Interest Tags
N/AStudy Type
ClinicalClinical Trial Details
Not applicableBroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
BIOLINK - TO INVESTIGATE AND DETERMINE IF TREATMENT WITH RAMATROBAN, ADMINISTERED FOR 28 DAYS TO HOSPITALIZED, NON-ICU PATIENTS WITH COVID-19 PNEUMONIA, REDUCES THE RISK OF SUBSEQUENT DEVELOPMENT OF PASC OVER THE ENSUING 11 MONTHS. PROVIDED DATA